A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE BLIND, DOSE-ESCALATION, MULTICENTER STUDY OF THE SAFETY, TOLERABILITY, EFFICACY AND PHARMACOKINETICS, OF A SINGLE INTRAVENOUS DOSE OF PF-04383119 IN JAPANESE PATIENTS WITH MODERATE TO SEVERE PAIN FROM OSTEOARTHRITIS OF THE KNEE
Sponsor: Pfizer
A PHASE2 clinical study on Osteoarthritis, Knee, this trial is completed. The trial is conducted by Pfizer and has accumulated 9 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2021 — Jul 2024 [monthly]
Completed PHASE2
Phase: PHASE1_PHASE2 → PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 4 earlier versions
-
Dec 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Jun 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .